



46. WO 90/11296;
47. WO 87/06941;
48. WO 98/28414;
49. WO 98/20895;
50. Great Britain Patent Application 966,818;
51. U.S. Patent 4,200,748;
52. U.S. Patent 5,849,742;
53. U.S. Patent 4,349,674;
54. Makino et al., Heterocycles, Vol. 26, pgs. 1215-1220 (1987);
55. Abstract of Iijima et al., Yakugaku Zasshi, Vol. 108, No. 5, pgs. 437-442 (1988);
56. Abstract of Cascieri et al., J. Biol. Chem., Vol. 274, No. 13, pgs. 8694-8697 (1999);
57. Abstract of O.S. Moustafa, Phosphorus, Sulfur Silicon Relat. Elem., Vol. 131, pgs. 49-57 (1997);
58. Abstract of Guillon et al., Pharm. Pharmacol. Commun., Vol. 4, No. 7, pgs. 319-324 (1998);
59. Abstract of Tomoda et al., Bull. Chem. Soc. Jpn., Vol. 71, No. 5, pgs. 1125-1135 (1998);
60. Abstract of Piras et al., Farmaco, Vol. 48, pgs. 1249-1259 (1993);
61. Abstract of Collins et al., Bioorg. Med. Chem. Lett., Vol. 2, No. 9, pgs. 915-918 (1992);
62. Abstract of Shinde et al., Indian Drugs, Vol. 27, pgs. 32-34 (1989);
63. Abstract of Iijima et al., Chem. Pharm. Bull., Vol. 37, No. 3, pgs. 618-620 (1989); and
64. Abstract of Mahajanshetti et al., Indian J. Chem., Vol. 12, No. 1, pgs. 54-56 (1974).

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed before the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,

Date: July 20, 2000

Elias J. Lambiris, Reg. No. 33,728  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



6. Kreymann et al., The Lancet, pgs. 1300-1304, December 5, 1987;
7. Rachman et al., Diabetologia, Vol. 40, pgs. 205-211 (1997);
8. Gutniak, M.D., Ph.D. et al., Diabetes Care, Vol. 17, pgs. 1039-1044 (1994);
9. Nauck et al., Diabetologia, Vol. 39, pgs. 1546-1553 (1996);
10. Creutzfeldt, M.D., F.R.C.P. et al., Diabetes Care, Vol. 19, pgs. 580-586 (1996);
11. Fehmann et al., Endocrinology, Vol. 130, pgs. 159-166 (1992);
12. Wang et al., Endocrinology, Vol. 136, pgs. 4910-4917 (1995);
13. Wang et al., The Journal of Clinical Investigation, Vol. 99, pgs. 2883-2889 (1997);
14. Edvell et al., Endocrinology, Vol. 140, pgs. 778-783 (1999);
15. Buteau et al., Diabetologia, Vol. 42, pgs. 856-864 (1999);
16. Xu et al., Diabetes, Vol. 48, pgs. 2270-2276 (1999);
17. Nauck et al., Diabetologia, Vol. 29, pgs. 46-52 (1986);
18. Holst et al., Diabetologia, Vol. 40, pgs. 984-986 (1997);
19. Nauck et al., Diabetologia, Vol. 36, pgs. 741-744 (1993);
20. Nauck et al., J. Clin. Invest., Vol. 91, pgs. 301-307 (1993);
21. Flint et al., J. Clin. Invest., Vol. 101, pgs. 515-520 (1998);
22. Naslund et al., Am J Clin Nutr, Vol. 68, pgs. 525-530 (1998);
23. Naslund et al., Drug News Perspect, Vol. 11, pgs. 92-97 (1998);
24. Ranganath et al., Gut, Vol. 38, pgs. 916-919 (1996);
25. Naslund et al., Digestive Diseases and Sciences, Vol. 43, pgs. 945-952 (1998);
26. Deacon et al., Diabetes, Vol. 44, pgs. 1126-1131 (1995);
27. Knudsen et al., European Journal of Pharmacology, Vol. 318, pgs. 429-435 (1996);
28. Horn et al., Receptors and Channels, Vol. 5, pgs. 305-314 (1998);
29. Adelhorst et al., The Journal of Biological Chemistry, Vol. 269, No. 9, pgs. 6275-6278 (1994);
30. Mechanism et al., The Journal of Biological Chemistry, Vol. 273, No. 29, pgs. 17979-17982 (1998);
31. Willms et al., Journal of Clinical Endocrinology and Metabolism, Vol. 81, No. 1, pgs. 327-332 (1996);
32. WO 97/32858;
33. FR 1 469 360;
34. EP 0 277 794 A2;
35. WO 98/52945;
36. WO 99/01442;
37. WO 96/30370;
38. WO 95/05378;
39. DE 3 826 603 A1;
40. EP 0 018 493 A1;
41. EP 0 216 299 A1;
42. EP 0 338 346 A2;
43. WO 95/24403;
44. WO 99/01423;
45. WO 91/11457;